Guidelines and definitions for research on epithelial-mesenchymal transition. by Yang, Jing et al.
UCSF
UC San Francisco Previously Published Works
Title
Guidelines and definitions for research on epithelial-mesenchymal transition.
Permalink
https://escholarship.org/uc/item/3ds2c3s9
Authors
Yang, Jing
Antin, Parker
Berx, Geert
et al.
Publication Date
2020-04-16
DOI
10.1038/s41580-020-0237-9
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
1 
 
Definitions and Guidelines for Research on Epithelial-Mesenchymal Transition 
  
Jing Yang1,#, Parker Antin2, Geert Berx3, Cédric Blanpain4, Thomas Brabletz5, Marianne Bronner6, 
Kyra Campbell7, Amparo Cano8, Jordi Casanova9, Gerhard Christofori10, Shoukat Dedhar11, Rik 
Derynck12, Heide L. Ford13, Jonas Fuxe14, Antonio Garcia de Herreros15, Gregory J. Goodall16, Anna-
Katerina Hadjantonakis17, Ruby J.Y. Huang18, Chaya Kalcheim19, Raghu Kalluri20, Yibin Kang21, 
Yeesim Khew-Goodall22, Herbert Levine23, Jinsong Liu24, Gregory D. Longmore25, Sendurai A. Mani26, 
Joan Massagué27, Roberto Mayor28, David McClay29, Keith E. Mostov30, Donald F. Newgreen31, M. 
Angela Nieto32, Alain Puisieux33, Raymond Runyan34, Pierre Savagner35, Ben Stanger36, Marc P. 
Stemmler5, Yoshiko Takahashi37, Masatoshi Takeichi38, Jean Paul Thiery39, Erik W. Thompson40, 
Robert A. Weinberg41, Elizabeth Williams42, Jianhua Xing43, Binhua P. Zhou44, Guojun Sheng45#.  
On behalf of The EMT International Association (TEMTIA) 
 
Author Address and ORCID ID:  
1) Departments of Pharmacology and Pediatrics, Moores Cancer Center, University of California, 
San Diego, 3855 Health Sciences Drive, La Jolla, California 92093-0819, USA. ORCID: 0000-
0001-8410-3549  
2) Department of Cellular and Molecular Medicine, University of Arizona, 1501 North Campbell 
Avenue, Tucson, Arizona 85724, USA. ORCID: 0000-0001-9066-7412 
3) Molecular and Cellular Oncology Lab, Department of Biomedical Molecular Biology, Ghent 
University; Cancer Research Institute Ghent (CRIG); VIB Center for Inflammation Research, 
Technologiepark 71, 9052 Ghent, Belgium. ORCID: 0000-0001-5770-2458  
2 
 
4) Laboratory of Stem Cells and Cancer, Université Libre de Bruxelles, 808, route de 
Lennik, 1070 Bruxelles, Belgium, ORCID:  0000-0002-4028-4322 
5) Department of Experimental Medicine 1, Nikolaus-Fiebiger-Center for Molecular Medicine, 
Friedrich-Alexander-University Erlangen-Nürnberg, Glücksstr. 6, 91054 Erlangen, Germany; 
ORCID: 0000-0003-2983-9048 
6) Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, 
CA, 91125, USA. ORCID: 0000-0003-4274-1862  
7) Department of Biomedical Science and Bateson Centre, University of Sheffield, Sheffield, 
United Kingdom. ORCID: 0000-0001-8573-4756 
8) Departamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de 
Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), IdiPAZ & Centro de Investigación 
Biomédica en Red de Cáncer (CIBERONC), c/ Arzobispo Morcillo 4, Madrid 28029, Spain. 
ORCID: 0000-0002-9446-0862 
9) Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and 
Technology / Institut de Biologia Molecular de Barcelona (IBMB-CSIC), Baldiri Reixac, 10, 
08028 Barcelona, Catalonia. ORCID: 0000-0001-6121-8589 
10) Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland. 
ORCID: 0000-0002-8696-9896 
11) Department of Biochemistry and Molecular Biology, University of British Columbia and 
British Columbia Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC, Canada 
V5Z1L3. ORCID: 0000-0003-4355-1657 
12) Departments of Cell and Tissue Biology, and Anatomy, University of California at San 
Francisco, San Francisco, CA, 94143, USA. ORCID: 0000-0003-4407-6990 
3 
 
13) Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, CO 
80045, USA. ORCID: 0000-0002-2860-9841 
14) Department of Laboratory Medicine (LABMED), Division of Pathology, Karolinska University 
hospital and Department of Microbiology, Tumor and Cell biology (MTC), Karolinska 
Institutet, Stockholm, Sweden. ORCID:  0000-0003-4576-9377 
15) Programa de Recerca en Càncer, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) 
and Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Doctor 
Aiguader 88, Barcelona E-08003, Spain. ORCID: 0000-0001-5270-0808  
16) Centre for Cancer Biology, An alliance of SA Pathology and University of South Australia, 
Adelaide, SA 5000, Australia. ORCID: 0000-0003-1294-0692 
17) Developmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer 
Center, New York NY 10065, USA. ORCID: 0000-0002-7580-5124 
18) School of Medicine, College of Medicine, National Taiwan University, 1 Ren-Ai Road Section 
1, Taipei, Taiwan, 10051. ORCID: 0000-0001-6376-3185 
19) Department of Medical Neurobiology, Institute for medical Research Israel-Canada and the 
Safra Center for Neurosciences, Hebrew University of Jerusalem, Hadassah Medical School, 
Jerusalem-Israel 9112102. ORCID: 0000-0002-4612-9438 
20) Department of Cancer Biology, Metastasis Research Center, MD Anderson Cancer Center, 
Houston, Texas. ORCID: 0000-0002-2190-547X 
21) Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA. ORCID: 
0000-0002-1626-6730  
22) Centre for Cancer Biology, an Alliance of SA Pathology and the University of South Australia, 
UniSA CRI Building, North Terrace, Adelaide, SA 5000, Australia. ORCID: 0000-0002-0473-
5392 
4 
 
23) Department of Physics, Northeastern University, Boston, MA 02115.  ORCID: 0000-0002-
8819-9055 
24) Department of Anatomic Pathology, The Division of Pathology and Loboratoy Medicine, The 
University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 
77030. ORCID: 0000-0002-3239-6658 
25) Department of Medicine (Oncology) and Department of Cell Biology and Physiology, ICCE 
Institute, Washington University, St. Louis, MO, USA ORCID: 0000-0001-7568-8151 
26) Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer 
Center, Houston, Texas 77030, USA. ORCID: 0000-0002-5918-4276 
27) Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering 
Cancer Center, 1275 York Avenue, New York, New York 10065, USA. ORCID: 0000-0001-
9324-8408 
28) Department of Cell and Developmental Biology, University College London, Gower Street, 
London WC1 E 6BT UK. ORCID: 0000-0001-9053-9613. 
29) Department of Biology, Box 90338, Duke University, Durham, North Carolina 27708, USA. 
ORCID: 0000-0001-8824-2183 
30) Departments of Anatomy and Biochemistry/Biophysics, University of California, San 
Francisco, School of Medicine, San Francisco, California 94143, USA. ORCID: 0000-0002-
8123-6247 
31) Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC, Australia.  
ORCID: 0000-0002-3467-6389 
32) Instituto de Neurociencias (CSIC-UMH) Avda Ramon y Cajal s/n. Sant Joan d´Alacant, Spain. 
ORCID: 0000-0002-3538-840X 
5 
 
33) Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon 
Bérard, Cancer Research Center of Lyon, Lyon, France. Present address: Institut Curie, PSL 
Research University, Paris, France. ORCID: 0000-0002-9938-3798 
34) Department of Cellular and Molecular Medicine, University of Arizona, 1501 North Campbell 
Avenue, Tucson, Arizona 85724, USA. ORCID: 0000-0002-7410-916X 
35) INSERM UMR 1186, Integrative Tumor Immunology and Genetic Oncology, Gustave Roussy, 
Fac. de medecine - Univ. Paris-Sud, University Paris-Saclay, 114 rue Edouard Vaillant,94805 
Villejuif Cedex France. ORCID: 0000-0002-8287-2229 
36) Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, PA 10104, USA. ORCID: 0000-0003-0410-4037 
37) Department of Zoology, Graduate School of Science, Kyoto University, Kitashirakawa, Sakyo-
ku, Kyoto 606-8502, Japan. ORCID: 0000-0002-1596-7527 
38) RIKEN Center for Biosystems Dynamics Research, 2-2-3 Minatojima-Minamimachi, Chuo-ku, 
Kobe 650-0047, Japan. ORCID: 0000-0002-9931-3378 
39) Guangzhou Regenerative Medicine and Health, Guangdong Laboratory,  190 Kai Avenue 
Science Park, Guangzhou, China 510530. ORCID: 0000-0003-0478-5020 
40) School of Biomedical Sciences and Institute of Health and Biomedical Innovation, Queensland 
University of Technology, Translational Research Institute, 37 Kent St., Woolloongabba, QLD, 
Australia 4102. ORCID: 0000-0002-9723-4924 
41) Whitehead Institute for Biomedical Research, Department of Biology, MIT Ludwig Center for 
Molecular Oncology, Massachusetts Institute of Technology, 455 Main Street, Suite #301, 
Cambridge, MA 02142. ORCID: 0000-0002-0895-3557 
42) Australian Prostate Cancer Research Centre-Queensland (APCRC-Q) and Queensland Bladder 
Cancer Initiative (QBCI), School of Biomedical Sciences and Institute of Health and 
6 
 
Biomedical Innovation, Queensland University of Technology, Translational Research Institute, 
37 Kent St., Woolloongabba, QLD, Australia 4102. ORCID: 0000-0002-3364-6655 
43) Department of Computational and Systems Biology, and UPMC-Hillman Cancer Center, 
University of Pittsburgh, Pittsburgh, PA 15232, USA, ORCID: 0000-0002-3700-8765 
44) Department of Molecular and Cellular Biochemistry, and UK Markey Cancer Center, 
University of Kentucky College of Medicine, Lexington, KY 40536, ORCID: 0000-0002-0983-
2060 
45) International Research Center for Medical Sciences (IRCMS), Kumamoto University, 2-2-1 
Honjo, Chuo-ku, Kumamoto 860-0811, Japan. ORCID: 0000-0001-6759-3785 
 
#Correspondence should be addressed to J.Y. (e-mail: jingyang@ucsd.edu) and G.S (e-mail: 
sheng@kumamoto-u.ac.jp). 
  
7 
 
Abstract: 
Epithelial-Mesenchymal Transition (EMT) encompasses dynamic changes in cellular organization 
between epithelial and mesenchymal phenotypes, which leads to functional changes in cell migration 
and invasion. A conserved set of inducing signals, transcriptional regulators, and downstream effectors 
of EMT has been implicated in a diverse range of physiological and pathological EMT events. Rapid 
expansion in EMT-oriented research is highlighted by over five thousand publications indexed by Web 
of Science in 2018 alone, warranting consensus-building among researchers for clarity in EMT 
nomenclature and guidelines for EMT research. Mediated by “The EMT International Association” 
(TEMTIA), this white paper is the outcome of a two year-long discussion among EMT researchers and 
aims to provide definitions and guidelines for EMT research in future publications. We trust that this 
white paper will help to reduce misunderstanding and misinterpretation of research data generated in 
various experimental models and promote fruitful cross-disciplinary conversation and collaboration 
through the identification of key questions arising in this field. While recognizing the importance of 
maintaining diversity in experimental approaches and conceptual frameworks, we emphasize that 
lasting contributions of EMT research to life sciences, especially in understanding developmental 
processes and in combatting cancer and other diseases, rests on adoption of a unified terminology to 
describe EMT, which this white paper strives to achieve.   
 
1. Introduction  
Epithelial-Mesenchymal Transition (EMT) is a cellular process during which epithelial cells 
downregulate their epithelial features and acquire mesenchymal phenotypes and behavior. EMT is 
triggered in response to signals that cells receive from their microenvironment. The epithelial state of 
the cells in which EMT is initiated is characterized by epithelial cell-cell junctions, apical-basal 
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polarity, and interactions with basement membrane. During EMT, these epithelial characteristics 
become repressed, and cells acquire mesenchymal characteristics due to changes in gene expression 
and post-translational regulation, displaying a fibroblast-like morphology and cytoarchitecture as well 
as increased migratory capacity. Furthermore, these now migratory cells often acquire invasive 
properties. 
 
EMT was first defined as a coherent process via research on early embryogenesis  1,2. It is now 
recognized to occur normally during early embryonic development to enable a variety of 
morphogenetic events as well as later in development and in the adult during wound healing. Moreover, 
EMT is activated during cancer pathogenesis and tissue fibrosis. The reverse process, known as 
Mesenchymal-Epithelial Transition (MET), also occurs frequently during development. A salient 
characteristic of EMT is that during the course of both developmental and pathological EMTs 
occurring in vivo, the transition from an epithelial to a mesenchymal state is often incomplete, resulting 
in cells that reside in intermediate states that retain both epithelial and mesenchymal characteristics. Of 
note, these intermediate states can be diverse depending on the biological context 3.  
 
The EMT research field has grown explosively over the last 20 years. More than half of all 
publications on EMT have appeared in the last five years (Fig. 1), and half of those address EMT in the 
context of cancer biology. The growing complexity and diversity of the EMT literature has resulted in 
the currently diffuse definitions of EMT and associated nomenclature. Thus, cell biologists have 
traditionally focused on shifts in the microscopically visible, profound changes in cell-cell interactions, 
cell motility, cytoskeletal organization, cell proliferation, and resistance to various stressors. Molecular 
biologists have focused on EMT-associated transcription factors (EMT-TFs) and how they act, often 
involving various chromatin modifications to orchestrate changes in EMT-associated gene expression. 
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Cancer biologists often emphasize the acquisition of various malignancy-associated cell phenotypes, 
notably invasiveness, dissemination, and the effects of cell responsiveness to various therapeutic 
modalities. These diverse portrayals of EMT do not reflect current experimental shortcomings. Rather, 
as we learn more about EMT-associated changes, the recognition of diversity in EMT phenotypic 
manifestations requires a more encompassing view of EMT, rather than a single narrow definition of 
this complex cell biological program.   
 
2. Purpose of this Consensus Statement 
 
The use of the term EMT in diverse areas covering developmental biology, cell biology, tissue 
homeostasis, and disease (notably cancer and fibrosis) has created discrepancies in data interpretation 
and persistent disagreement 4-9, largely because the plasticity and heterogeneity of EMT programs have 
been insufficiently considered. EMT was originally described as an important process in embryonic 
development during which epithelial cells underwent a phenotypic transformation to mesenchymal 
cells. Early analyses and validations in cell culture focused on the phenotypic changes using a limited 
set of molecular markers. However, the identification of EMT as a crucial program in cancer initiation 
and progression indicated that EMT involves more than the original developmental EMT programs and 
that different variations of the EMT-program clearly exist.    
 
As the complexity of EMTs and EMT regulators in cancer becomes increasingly appreciated, there is a 
need for the community of EMT researchers to agree on a number of key issues. These include proper 
description of EMT-related phenomena, definitions of major EMT-related terms, diverse versions of 
EMT and their context-dependent regulation by EMT regulators and the relationship between core and 
non-core EMT functions of EMT-TFs; in the context of cancer pathogenesis, the contributions of 
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genetic alterations, the complex input of the changing tumor environment, and EMT-like changes in 
non-epithelial cancers, such as melanoma, sarcoma and leukemia must also be considered. Provoked 
by a passionate town hall discussion in its 2017 meeting, the EMT International Association  
(TEMTIA; https://temtia.org) proposes the following guidelines to define the EMT program, its 
phenotypic plasticity, and the resulting multiple intermediate epithelial/mesenchymal states. By 
building such a consensus on EMT-related concepts, we aim to eliminate semantic problems in the 
EMT debate and facilitate genuine cross-disciplinary discussion on the roles of EMT in normal 
developmental and pathological conditions.  
 
3. A brief history of EMT 
Modern EMT studies began with research aimed at understanding tissue morphogenesis during 
development, cell behavior in culture, and carcinoma invasiveness in cancer progression. Elizabeth 
Hay recognized the importance of EMT in embryogenesis 1 and began to discuss the concept of 
“epithelial-mesenchymal transformation” in the late 1970s. The EMT concept was examined 
subsequently in the context of neural crest formation 10,11, heart valve formation 12 and Müllerian duct 
regression 13, and in epithelial tissue explants in vitro 14. This “epithelial-mesenchymal transformation” 
process was alternately referred to as “epithelial-mesenchymal transition” to distinguish it from the 
process of neoplastic transformation used by the cancer community.  “Epithelial-mesenchymal 
transition” became the consensus usage after the 1st TEMTIA meeting that brought the field together in 
2003. 
A variety of observations originating more than a quarter century ago described EMT programs 
induced by a diverse array of contextual signals. For example, cultured amnion cells were 
“transformed” from an epithelial phenotype into fibroblast-like cells in response to leukocyte medium 
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15. Endocardial cells underwent EMT in response to signals from adjacent cardiac muscle 16. 
Hepatocyte Growth Factor (HGF) was found to induce transformation of epithelial cells into migratory 
fibroblasts 17. Fibroblast growth factor 1 (FGF1) induced an “epithelial plasticity” response in bladder 
carcinoma 18, connecting EMT to cancer. TGF-β, overexpressed in cancers and required for cardiac 
EMT 19, was shown to act as a potent EMT inducer in cultured cells 20. These observations provided 
the first indications that diverse extracellular signals, including soluble factors and, quite possibly, 
components of the extracellular matrix (ECM) could act together to evoke EMT programs in 
responding cells.  
  
These early descriptive studies shed little light on the mechanisms operating within individual cells 
that enable induction of EMT programs. Discoveries in the field of Drosophila developmental genetics 
revealed the identities of master regulators of these programs, such as the transcription factors Snail 
and Twist, which act pleiotropically to orchestrate mesoderm formation during gastrulation 21. The 
involvement of related transcription factors in chordates testified to the high degree of conservation of 
these factors during the course of metazoan evolution, and thus the utility of using various 
developmental models to study EMT regulation in human cells.  
 
Research aimed at identifying molecular regulators of EMT began on a large scale in the 1990s. For 
example, the identification of the Snail-related transcription factor Slug (Snai2) as an inducer of EMT 
during chick gastrulation and neural crest cell formation illustrated that specific transcription factors 
(EMT-TFs) can act as key upstream regulators of EMT 22. The finding that Slug expression can 
convert epithelial carcinoma cells into mesenchymal derivatives strengthened the connection between 
embryonic EMT and cancer progression 23. This notion was reinforced by the observation that the 
Snail family transcription factors are capable of inducing EMT and invasiveness in normal epithelial 
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cells, in part through transcriptional repression of the gene encoding E-cadherin 24-27. Additional EMT-
TFs, notably E47, Twist1, Zeb1 and Zeb2, were identified through their ability to evoke morphological 
and molecular changes associated with EMT 28-31.  It is important to note that these EMT-TFs usually 
co-operate with one another to orchestrate EMT programs.  Extensive studies also reveal that various 
upstream EMT -inducing signals could impinge on these EMT-TFs, doing so via transcriptional and 
post-transcriptional regulation.  
 
As a better understanding of the inductive signals and transcriptional control of EMT evolved, it 
became apparent that activation and execution of EMT programs do not require changes in DNA 
sequence and can be reversible. This made it clear, in turn, that EMTs represent complex epigenetic 
regulatory programs, much like those operative during many steps of development. During 
development, some cell populations may undergo multiple rounds of EMT and MET, indicating 
substantial phenotypic plasticity. For example, during renal morphogenesis, the epithelial cells lining 
renal vesicles are derived from renal mesenchymal cells via MET, while these mesenchymal cells are 
descendants of epithelial cells in the epiblast via EMT 32. During somite formation, paraxial 
mesenchyme cells undergo MET to form epithelial somites, which in turn undergo EMT to give rise to 
the sclerotome 33. Likewise, during pathogenesis of cancers and fibrosis, EMT programs are activated 
to various extents and are often reversible, revealing a plasticity that can yield cells residing in a 
spectrum of phenotypic states between the fully epithelial and fully mesenchymal endpoints of this 
program. This issue presents a major challenge to the EMT research community:  How to best capture 
the diversity and plasticity of EMT programs operating in various biological contexts. 
 
4. EMT in development, cancer, and fibrosis 
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A driving paradigm for the growth of this research field is that EMT operates in normal tissues during 
development and wound healing, but is also a driver in the pathogenesis of cancer and fibrosis. The 
common starting point of diverse EMTs is a downregulation of certain epithelial phenotypes. 
Importantly, however, the EMT programs do not operate as binary switches that shunt cells from fully 
epithelial to fully mesenchymal extremes. Instead, cells activate EMT programs to differing extents, 
yielding cells that land at various stopping points along the E-to-M phenotypic spectrum. At present, it 
remains unclear whether there are discrete phenotypic states arrayed along this spectrum or, 
alternatively, a continuum of such states lacking distinct, definable boundaries. The extent to which 
such intermediates represent stable states in specific biological contexts is also unclear. A continuum 
of EMT intermediate states may enable rapid interconversion between cells possessing various 
combinations of these traits, a process viewed as having high phenotypic plasticity. Additionally, it is 
likely that the phenotypic states between the fully epithelial and fully mesenchymal endpoints cannot 
be arrayed along a linear spectrum, and that multiple alternative paths can operate to enable an 
epithelial cell to advance toward a mesenchymal state. Finally, cells activating EMT programs in adult 
tissues under pathological conditions commonly express combinations of epithelial and mesenchymal 
markers and rarely complete the entire EMT program, suggesting that "partial EMTs" represent the 
norm rather than the exception.  
Development: During animal development, cells of epithelial origin often migrate long distances from 
their points of origin to their final destinations. These migrations depend on cells transitioning to a 
more mesenchymal state through EMT in order to enable migration, and in many cases the resulting 
cells then undergo permanent or temporary reversal to an epithelial state through MET (e.g., endoderm 
cells) or switch to another state (e.g., neural crest). A great degree of morphological variability is 
associated with epithelial cells that participate in developmental EMTs, ranging from cells possessing 
fully formed epithelial cell-cell junctions and an underlying basement membrane, such as the 
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pluripotent epiblast cells of amniotes34, to the primitive epithelial cells giving rise to mesendoderm in 
Xenopus and fish, which exhibit only apical-basal polarity and incompletely assembled junctions35. In 
many cases, the quasi-mesenchymal state is not reached through a complete loss of cell-cell junctions, 
but instead by changes in the nature and dynamics of junction formation and dissolution, which may 
explain how cells with mesenchymal characteristics can exhibit collective cell migration36, i.e. the 
migration of cohorts of cells that appear to be held together by various types of cell-cell junctions. 
Such plastic, quasi-mesenchymal phenotypes are observed in cells that migrate collectively and form 
cadherin-based cell-cell contacts, as seen in Drosophila, zebrafish, Xenopus and in mouse endoderm 
and mesoderm cells37-42, neural crest cells of zebrafish, chick, and Xenopus43,44, and cells that migrate 
while forming only transient cell-cell contacts, such as germ cells of zebrafish45. It is important to note 
that not every migratory process employed by epithelial cells involves EMT, such as chicken epiblast 
morphogenesis before the formation of the primitive streak 46. 
 
Cancer: During the multi-step progression of carcinomas, initially benign, epithelial cells acquire 
certain distinctly mesenchymal traits and thereby develop the ability to invade locally and disseminate 
to distant tissues. Much of this phenotypic progression depends on the activation of EMT programs 3,47-
51.  Carcinoma cells may be able to perform collective migration locally without activating EMT 
programs, possibly using collective migration mechanisms similar to those used during development.  
However, it is unclear whether primary carcinoma cells can complete the entire process of metastatic 
dissemination without activating, at least transiently, components of the EMT program. The residence 
of individual carcinoma cells in intermediate E/M states (i.e., partial EMTs) echoes the behavior of 
epithelial cells during normal development. In this way, cancer cells proceed through a gradation of 
phenotypic states, each associated with combinations of epithelial and mesenchymal markers 3,51,52.  
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Activation of alternative EMT programs and progression of individual cells to different states along the 
E-to-M spectrum can generate extensive phenotypic heterogeneity within tumors. Supporting this 
notion, multiple E/M subpopulations with distinct chromatin landscapes and gene expression 
signatures have been reported in skin and mammary primary tumors, and these subpopulations are 
often spatially localized within a tumor 53. Moreover, hybrid E/M states are enriched in the circulating 
tumors cells (CTCs) released by primary and disseminated breast and lung cancers 54,55, ostensibly 
reflecting the cellular heterogeneity seen within corresponding primary tumors. Such phenotypic 
plasticity and heterogeneity may provide cancer cells with substantial adaptability, enabling them to 
respond to a variety of external cues and physiologic stresses 3,49,51,52,56,57. Thus, since tumor cells 
encounter diverse microenvironments as they navigate the multiple steps of the metastatic cascade, 
various intermediate/hybrid E/M phenotypes may be favored and better adapted for survival in these 
distinct environments, such as blood and lymphatic vessels and primary and secondary tumor sites. 
The tissue-of-origin of the tumor cell, specific combinations of expressed EMT-TFs, and modifications 
of chromatin may also determine the phenotypic heterogeneity arising from residence in various hybrid 
E/M states. 
 
The diversity of EMT-associated cancer cell phenotypes is reflected in discrepancies in experimental 
and histopathological observations of human tumors, fueling a long-standing debate regarding the 
role(s) of EMT in cancer progression 4,5,58-60. Such differences are often due to the use of different 
EMT-markers and the analysis of particular EMT-TFs as markers of this program; in addition, the 
EMTs operating in different tissues may differ from one another. For instance, Snai1 and Twist1 were 
both shown to be important for metastasis in the PyMT-driven breast cancer model 61,62, but 
dispensable for metastasis in a pancreatic cancer model 7, which instead depends on Zeb1 63. Further 
complexity comes from the observation that carcinoma cells undergoing a partial EMT can shed their 
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epithelial phenotype through post-translational mechanisms 64, making it challenging to interpret 
studies that rely solely on the perturbation of transcriptomes by EMT-TFs. These and other examples 
indicate that the version of EMT programs and the functions of involved EMT-TFs are tissue context-
dependent. Moreover, as often seen during the course of embryonic development, cancer-associated 
EMT is likewise only activated partially and transiently, making end-stage markers of a fully 
mesenchymal state uninformative in cancer studies. Further complicating the situation is the fact that 
EMT programs have been linked to additional traits, possibly yielding traits that are not associated 
with canonical EMT regulation, such as the stemness, survival, metabolic changes, and, in the case of 
cancer, resistance to anti-cancer therapeutic drugs 65,66.  
Fibrosis: EMT has also been observed to occur and play a role in diverse types of fibrosis (including 
in the lung, liver and kidney) with EMT-TF expression shown to be a pre-requisite for fibrosis 
development/progression in mouse models 3. As in cancer progression, the role of EMT in organ 
fibrosis has been the subject of active debate. A central issue in this debate has been the origin of the 
myofibroblasts that accumulate in fibrotic tissues. These cells represent a specialized fibroblast 
population involved in collagen secretion and thus the development and progression of interstitial 
fibrosis that lies at the heart of this disease. Early lineage tracing studies supported the EMT-driven 
conversion 67, but subsequent tracing analyses do not provide compelling evidence of epithelial cells as 
precursors of fibrosis-associated myofibroblasts 68. More recent studies show that renal epithelial cells 
undergo a partial EMT that is crucial for disease progression but do not directly contribute to the 
formation of the myofibroblast population 68,69. Instead, they lose their normal tubular function, and 
these damaged cells relay paracrine signals to the interstitium, reshaping the microenvironment 
through the release of TGF-β that converts existing fibroblasts into myofibroblasts,and the secretion of 
additional cytokines and chemokines that are likely to recruit macrophages to the stroma. Hence, 
damaged renal epithelial cells promote both fibrogenesis and inflammation, these representing 
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hallmarks of renal fibrosis 69,70. While the debate concerning the contribution of EMT to different types 
of fibrosis will likely continue, the demonstrated requirement of EMT-TF expression strongly suggests 
that activation of EMT is indeed required for the development of several types of fibrosis.  
 
5. Definitions of EMT and its associated terms 
To facilitate investigation of multifaceted EMT processes and discussion among diverse groups of 
EMT researchers, we propose the following definitions of EMT and its associated terms to stand as a 
reference. 
  
a)   EMT (epithelial-mesenchymal transition) 
A multifaceted and often reversible change in cellular phenotypes during which epithelial cells lose 
their apical-basal polarity, modulate their cytoskeleton and exhibit reduced cell-cell adhesive 
properties. Cells may individually or collectively acquire mesenchymal features and increase motility 
and invasive ability. Typically, a switch in intermediate filament usage from cytokeratins to vimentin 
is observed after a complete EMT. Cortical actin filament in epithelial cells also undergoes marked 
rearrangement during EMT. While characteristics of fully epithelial cells are relatively clearly defined, 
our current knowledge does not allow us to define the mesenchymal state with specific cellular 
characteristic or molecular markers that are universal end-products of all EMT programs.  
  
b)   MET (mesenchymal-epithelial transition) 
Reciprocal changes in cellular phenotype that reverse EMT-induced phenotypes, during which 
mesenchymal-like cells may acquire apical-basal polarity, re-organize their cytoskeleton, and exhibit 
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increased cell-cell adhesion, resulting in an organized epithelium. MET occurs during embryonic 
development (e.g.,  cardiac development, kidney morphogenesis, somite formation) and cancer. 
  
c)   EndoMT (endothelial-mesenchymal transition) 
Similarly to epithelial cells, endothelial integrity depends on cell-cell junctions, apical-basal polarity 
and interactions with an underlying basement membrane. Endothelial-mesenchymal transition 
(EndoMT) more accurately indicates the affected cell population, and resembles EMT in most aspects 
except for the replacement of E-cadherin by VE-cadherin. EndoMTthereby enables endothelial cells to 
attenuate or deconstruct their functional integrity and apical-basal polarity, to acquire motile and 
invasive behavior, and to activate changes in gene expression that are driven by certain EMT-TFs. 
Similar to EMT in epithelial cells, endothelial cells that have activated EndoMT programs exhibit a 
variety of intermediate or partial phenotypes, as discussed above for EMT. EndoMT was initially 
described during embryonic heart development 71 and subsequently in the context of cardiac fibrosis 72.  
 
d)   EMP (epithelial-mesenchymal plasticity) 
We favor the use of EMP to describe the ability of cells to adopt mixed E/M features and to 
interconvert between intermediate E/M phenotypic states arrayed along the epithelial-mesenchymal 
spectrum that cannot be easily distinguished based on our current understanding. This plasticity has 
been variably referred to as partial EMT, hybrid E/M status, metastable EMT state, EMT continuum, 
and EMT spectrum, in all of which cells express a mixture of epithelial (e.g., cytokeratins) and 
mesenchymal (e.g., migration) features and markers. EMP indicates an ability to move readily between 
these various states, while the stability of these various states varies in different biological contexts. 
EMP is widely observed in development, wound healing, and cancer. In addition to a mesenchymal-
type of migration, as observed during mesoderm formation, EMP can also participate in collective 
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migration, e.g., during tubulogenesis and wound healing. EMP also accounts for the reversibility of the 
EMT program. Epithelial cells going through EMT give rise to cell populations that may enter 
reversibly into states with various proportions of epithelial and mesenchymal features. EMP is thought 
to provide cells the fitness and flexibility to fulfill the diverse requirements during the course of both 
developmental and pathological processes. 
 
e)  Definition of EMT transcription factors 
In many if not most settings, both in cell culture and in vivo, EMP involves some degree of 
transcriptional regulation. Several transcription factors (TFs) belonging to the Snail, Twist and Zeb 
families have been found to control cell-cell adhesion, migration and ECM degradation, and to play 
evolutionally conserved central roles in the operations of EMTs observed in various biological settings 
in various organisms (Table 1). In fact, all of the developmental EMT processes described to date 
involve at least one member of these families of core EMT-TFs.  
 
Yet other TFs have been shown to affect EMT in certain contexts (Supplemental Table 1). However, 
these transcription factors are also involved in other cellular processes (e.g., proliferation, apoptosis, 
stemness). Typically, these responses involve regulation of cellular fate, survival and dynamics. In 
addition, many of the EMT-TFs are also expressed in non-epithelial cells, ranging from fibroblasts to 
hematopoietic precursors, and in cancer types involving non-epithelial derivatives (melanoma, 
glioblastoma, leukemia), where they play important roles during tumor progression, often beyond 
classic EMT phases. While we use EMT-TFs to describe all transcription factors associated with EMT, 
it is important to keep in mind that their expression alone does not indicate an EMT process.   
 
6. Recommendations on the features that define the core EMT program 
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6.1: EMT status cannot be assessed based on one or a small number of molecular markers.  
EMT represents changes of cell behavior involving loss of certain epithelial characteristics and gain of 
certain mesenchymal traits. The complex series of cell-biological changes occurring during EMTs 
require the cooperation of a large number of molecular factors. Based on their involvement in the 
process, these factors can be divided into three groups: EMT-inducing signals, EMT-associated 
transcription factors (EMT-TFs), and EMT markers that define and create various epithelial and 
mesenchymal cell characteristics. In the literature, diverse cellular and molecular descriptors have been 
used to define EMT in various biological systems, representing a major source of confusion. For 
example, some studies define partial loss of E-cadherin as an indication of EMT, while others argue 
that the maintenance of certain levels of expression of epithelial markers, such as cytokeratins, is 
indicative of cells not having undergone EMT. Given the complex manifestations of the EMT program, 
it has become clear that conclusions concerning the actions of EMT cannot rely solely on a few salient 
molecular markers, such as E-cadherin and vimentin 73.  
 
More importantly, the use of various EMT molecular markers to characterize the phenotypic state of 
individual tumor cells has revealed that such cells, as described earlier, can simultaneously express 
both epithelial and mesenchymal genes. The core EMT-TFs are often co-expressed in various 
combinations in order to orchestrate complex EMT programs and involve various members of EMT-
TF families, such as Snai1 vs. Snai2, Zeb1 vs. Zeb2, depending on specific biological context 74. 
Importantly also, post-transcriptional regulation of EMT regulators at both the mRNA and protein 
levels is critical in controlling the EMT outputs. Such regulation is often neglected in studies that use 
RNA expression exclusively to survey EMT molecular markers.  A focus on defining EMT programs 
based exclusively on the expression of specific molecular markers such as these underrepresents the 
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enormous complexity and plasticity of the EMT programs in diverse developmental and pathological 
settings.  
  
6.2: Primary criteria for defining the EMT status should be changes in cellular properties 
together with a set of molecular markers, rather than relying solely on molecular markers.  
One major feature that unites all variant EMT programs is the initial attenuation or deconstruction, to 
various degrees and with diverse manifestations, of the epithelial phenotype. Epithelial cells harbor 
complexes mediating cell-cell interactions, most notably adherens junctions, tight junctions and 
desmosomes. Apical-basal polarity guides the proper organization of tight junctions, adherens 
junctions and desmosomes in epithelial cells. The polarity complexes, including the Par, Crumbs, and 
Scribble complexes75-77, define the apical vs. basal-lateral domains of an epithelial cell. During the 
early phase of EMT, loss of apical-basal polarity is often the first event to be observed and can lead to 
the destabilization of adhesion complexes, such as the tight junctions and adherens junctions at the 
lateral membrane 78,79 , as well as activation of EMT-TFs 80. The decrease or loss of epithelial adherens 
junctions and desmosomes occurs via transcriptional repression by the core EMT-TFs of genes 
encoding junction proteins. . The cytoplasmic relocalization of adherens junction proteins, such as E-
cadherin, via post-transcriptional regulation is also an early feature of EMT initiation in various EMT 
models 81.  
 
Another key function of the EMT programs is to provide stationary epithelial cells with the ability to 
migrate by invading through extracellular matrices secreted by both epithelial and mesenchymal cells. 
Thus, during EMT, epithelial cells often need to breach the basement membrane in order to migrate 
away from their epithelium of origin 34,82. Migration of cells that have undergone EMT does not 
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necessarily require cells to lose all epithelial features, and a switch of intermediate filaments from 
cytokeratin to vimentin can facilitate cell migration. Depending on the extent of cell-cell adhesion loss, 
epithelial cells can migrate as single cells in a mesenchymal manner or collectively while remaining 
attached with one another via weakened but still operative cell-cell interactions. This indicates that the 
breakdown of these tightly regulated epithelial structures, the gain of motility and the ability to degrade 
ECM during EMT cannot simply be represented by the absence or presence of the expression of 
selected markers. Furthermore, complex post-translational modifications of key proteins play critical 
roles in governing these complex processes. For these reasons, EMT or MET events should be 
described as functional changes of the cell-biological properties rather than focusing largely on 
changes of a few readily monitored molecular markers. It is with this perspective that our 
understanding of EMT could faithfully reflect the functional purpose of EMT during developmental 
and pathological events (Fig. 2).  Therefore, whenever it is experimentally feasible, EMT should be 
assessed by cellular properties together with multiple molecular markers. 
 
6.3: EMT-TFs and other molecular markers are valuable indicators of EMT, but should be 
assessed in conjunction with changes in cellular characteristics to define EMT.  
The morphological and functional changes during EMT are often the result from changes in gene 
expression. Many, but not all, changes in EMT gene expression result directly or indirectly from 
actions of EMT-TFs, which play key roles in driving EMT programs. Indeed, most EMT programs are 
associated with activation of expression of one or several core EMT-TFs. While core EMT-TFs often 
initiate EMT-associated changes in gene expression (Table 1), a large number of other EMT-TFs and 
numerous microRNAs and lncRNAs have also been shown to contribute to or play critical roles in 
diverse EMTs (Supplementary Table 1). Decreased association between β-catenin and p120-catenin to 
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E-cadherin, achieved by post-translational modifications,can also greatly weaken the adhesive 
functions of adherens junctions. Reduced expression of junctional and polarity proteins is often visible 
during EMT. Depending on the cell type and extent to which cells advance through an EMT program, 
cells undergoing an EMT may begin to express vimentin, suppress cytokeratin, shift expression of key 
integrins etc. These changes in gene expression are often seen as indicative of EMT or as markers of 
EMT, although, considering the extensive variations in EMT, their overall value in the diagnosis of 
EMT needs to be considered with caution. Beyond this small set of commonalities, it is difficult to 
define other changes as contributing universally to all the diverse manifestations of EMT programs that 
have been described in the rapidly expanding literature. Furthermore, our current knowledge does not 
allow us to know whether there is a linear succession of cell-biological changes as cells advance 
progressively through an EMT program, or whether a diverse series of routes radiates in multiple 
directions from the starting point of attenuation or loss of epithelial junctions.  
 
6.4: Finding reliable EMT markers requires a combinatorial approach, together 
withdistinguishing between EMT-associated and non-EMT-associated functions. 
An analysis of EMT status often requires the use of markers specific to a specific biological context.  It 
may also be critical to assess the position of cells along the EMT spectrum using a standardized set of 
criteria in a specific biological context. Obtaining quantitative EMT marker measurements should 
always be coupled with cellular and functional analyses of the EMT status as described above. 
Importantly, recent studies have linked EMT to various other cellular programs and functions, 
including cancer cell stemness, resistance to apoptosis, genome instability, cancer drug resistance, and 
metabolic adaptation. Many components of EMT regulatory pathways, including EMT-TFs, also affect 
other important cellular phenotypes and are themselves regulated through diverse signals that may or 
may not involve canonical EMT. For example, EMT-TFs, such as Snai1/2 and Twist1, also regulate 
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cell survival and cancer drug resistance 66,83, which are currently unknown to be due to their EMT 
functions or not. Likewise, many extracellular matrix remodeling proteins that are important in 
breaching basement membrane can be regulated in both EMT-dependent and -independent manners. 
Furthermore, while cells may switch to a different cell fate upon EMT, EMT represents changes of 
epithelial cell characteristics to more mesenchymal cones, which is independent of cell differentiation 
or dedifferentiation. Therefore, it is important to note that the cell biological definition of EMT strictly 
refers to the core EMT program, while we should keep these associated phenotypes in mind when 
examining the impact of EMT in various biological settings.  
 
7. Conclusions and implications for the future of EMT research 
 
Fifty years and over 36,000 publications after Betty Hay’s pioneering observations, the concept of 
EMT has now been widely applied in biomedical research. It provides a unifying framework for 
developmental and cancer studies, which is evidenced by the exponentially growing number of EMT-
related publications. Such a framework holds the promise of far-reaching breakthroughs in cancer 
diagnosis and treatment for cancer biologists, and for bridging the gap in understanding normal and 
pathological epithelial organization and morphogenesis for developmental and cell biologists. To 
realize this promise, it is desirable for the EMT community to reach a consensus on the definition of 
EMT-related terms as outlined in the previous sections and on the conceptual framework of 
approaching EMT research as a cell biological process with quantifiable molecular descriptors and 
cellular readouts. All co-authors of this white paper agree to use the terms that are defined in this white 
paper in future research publications and recommend other researchers in the EMT and the larger 
biological research community also follow these guidelines. Only by minimizing semantic 
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misinterpretation and data miscommunication can we begin to appreciate the diversity of individual 
EMTs and uncover conserved themes in EMT regulation in development and disease. 
  
Studies using cell lines, developmental systems and cancer models have revealed a diversity of EMT-
induced phenotypes and highlighted the remarkable complexity in the execution and regulation of 
EMT. Looking forward, to decipher the complexity and plasticity of the EMT program, we propose 
that EMT research, while anchored in traditional developmental, cell and cancer biology, should be 
explored within a broader conceptual context. The EMT field has in recent years attracted the interest 
of a diverse group of researchers with their expertise in systems biology, biophysics, stem cell biology, 
pathology and mathematical modeling. This represents remarkable strength and will surely enable 
genuine cross-disciplinary collaborations. We expect that future EMT studies will apply multi-
disciplinary approaches to gain increased mechanistic understanding of various EMT events. One open 
question in the cancer EMT field is the extent to which stabilization of specific hybrid E/M states or 
switches between E/M states in a dynamic fashion in response to distinct microenvironmental cues 
favors the metastatic process. With many important factors to EMT remaining insufficiently explored, 
advancing EMT research requires innovation in investigative tools for single-cell level studies of 
developmental and cancer EMTs. This includes single-cell live imaging, lineage tracing, gene 
expression analyses, and studies of genetic and epigenetic modifications. Finally, a combination of 
mathematical modeling with carefully constructed experimental analyses will be fruitful to gain 
mechanistic understanding of EMT plasticity.  
 
Another major challenge will involve the translation of the existing concepts of EMT heterogeneity 
and plasticity into clinical practice.  While we are far from understanding the full consequences of 
EMT heterogeneity, several clinical trials already incorporate the notion of dynamic EMT plasticity, 
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thereby opening the way for novel therapies exploiting EMT heterogeneity. Promising advances will 
come from single-cell sequencing of normal tissues, primary tumors, circulating tumor cells, and 
disseminated metastatic lesions, together with cellular analyses and functional validations, in order to 
better capture the diversity and plasticity of EMT and to reveal the underlying molecular alterations 
following tumor progression and therapy response. An increasing understanding of the manifestations 
and underlying mechanisms of EMTs offers the potential for targeted therapy to prevent cancer 
metastasis. For example, while inhibition of EMT-associated changes may reduce cancer cell 
dissemination in early-stage carcinoma, preventing MET in disseminated tumor cells might inhibit 
metastatic outgrowth in distant organs. Experimental and clinical studies show that resistance arising to 
various therapies, including chemotherapies and immunotherapies, is tightly associated with EMT 
phenotypes 83. These studies suggest that targeting EMT, or the cells capable of expressing it, hold 
promise in overcoming therapy resistance, a major challenge to cancer treatment.  
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TF 
Name 
Type Key References reporting the original discoveries 
  Development Cancer Fibrosis 
Snai1 
(Snail) 
zinc finger Boulay et al., 1987 
84; Nieto et al., 1992 
85 
Batlle et al., 2000 24; 
Cano et al., 2000 25 
Boutet et al., 2006 86 
Snai2 
(Slug) 
zinc finger Nieto et al., 1994 22 Savagner et al., 1997 
23 
 
Zeb1 zinc finger Funahashi et al., 
1993 87 
Grooteclaes and 
Frisch, 2000 
Oba et al., 2010 88 
Zeb2 
(SIP1) 
zinc finger Verschueren et al., 
1999 89 
Comijn et al., 2001 30 Oba et al., 2010 88 
Twist1 bHLH Thisse et al., 1988 90 Yang et al., 2004 29 Kida et al., 2007 
 91; Lovisa et al., 2015 
70 
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Figure legends: 
 
Figure 1. Growth of the primary literature in EMT. The first experimental analysis of EMT in 
development was published in 1979. The relationship of EMT to growth factors was found in 1989. 
Transcriptional regulation of EMT was identified in 1994. Subsequent growth was stimulated by 
linkage to metastasis, organ fibrosis and stem cells. Growth in the field has been logarithmic since the 
time of the first TEMTIA meeting in 2003. Graph indicates primary papers published each year by a 
search in the Web of Science database. Abstracts and reviews were excluded. The total number of 
publications for 2018 exceeded 5000 papers. 
 
 Figure 2. EMT diversity represented by an epithelial-mesenchymal plasticity model. Various 
cellular features associated with an epithelial or a mesenchymal cell state are found in a range of 
combinations in cells in different developmental contexts and to different degrees. The accumulated 
loss or gain of epithelial/mesenchymal characteristics pushes a cell towards various intermediate states 
(Bottom left and right) in both a fluid and reversible manner between a complete epithelial (Top left) 
and a complete mesenchymal (Top right) state. 
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Additional Transcription Factors associated with EMT 
TF Name Type of factor References 
  Development Cancer Fibrosis 
Alx1 homeobox Saunders & 
McClay, 2014 
Yuan et al., 2013 
 
- 
AP1 (Jun/Fos 
Atf) 
Ap1 Reichmann et al., 
1992 
Bakiri et al. 2015 Alcorn et al., 
2009 
Brachyury (T) T-box Beddington et al., 
1992 
Fernando et al., 
2010 
Sun et al., 2014 
CBF-A (NF-
YA) 
CCAT box 
binding 
- Venkov et al., 2007 Venkov et al., 
2007 
E2-2 (TCF4) 
(TCF7L2) 
bHLH Sobrado et al., 
2009 
Sobrado et al., 
2009 
Contreras et al., 
2016 
E47 (TCF3) bHLH Perez-Moreno et 
al., 2001 
Perez-Moreno et al., 
2001 
Slattery et al., 
2006 
Erg ETS Saunders & 
McClay, 2014 
Petrovics et al., 
2005 
- 
Ets1 ETS  Fafeur et al., 1997 Nakayama et al., 
1996 
Nakamura et al., 
2004. 
FoxC2 (FoxB) Forkhead Saunders & 
McClay, 2014 
Mani et al., 2007 Sipos & 
Galamb, 2012 
GATA4/6 
(Srp) 
GATA Campbell et al, 
2011 
- - 
Goosecoid 
(GSC) 
homeobox Blum et al., 1992 Hartwell et al., 
2006 
- 
HoxB7 homeobox - Wu et al, 2006 - 
Id1 HLH Jen et al., 1996 Tobin et al, 2011 Li et al., 2007 
KLF2 Sp/KLF Chiplunkar et al., 
2013 
- - 
Klf4 Klf Liu et al., 2012 Lin et al., 2012 Tiwari et al., 
2013 
KLF6 (Z9f) Sp/KLF - - Holian et al., 
2008 
KLF8 Sp/KLF - Wang et al, 2007 - 
NF-b NF-B/Rel  DeLaughter et al., 
2016 
Huber et al, 2004 Sunami et al., 
2012 
Prrx1 Paired related 
homeobox 
Ocana et al. 2012 Ocana et al., 2012; 
Takano et al., 2016 
Gong et al., 
2017 
Runx2 Runt-related Tavares et al. 2017 Pratap et al., 2005 Mummler et al., 
2018 
Six1 homeobox Grifone et al., 2005 Micalizzi et al., 
2009; McCoy et al., 
2009 
Smith et al., 
2008 
Sox4 homeobox Zhang et al, 2012 Liu et al., 2006 Xiao et al., 2015
 2
Sox9 homeobox Akiyama et al., 
2004 
Acevedo et al., 
2007 
Hanley et al., 
2008 
Tbx3 T-box Singh et al., 2012 Rodriguez et al. 
2008 
Wensing & 
Campos, 2014 
Tead 
(Yap/Taz) 
Tead Diepenbruck et al., 
2014 
Overholtzer et al., 
2006 
Seo et al 2016 
Tgif1 homeobox Saunders & 
McClay, 2014 
Xiang et al., 2015 - 
Twist2 
(Dermo1) 
bHLH - Ansieau et al., 2008 Grunz-
Borgmann et al., 
2017 
 
Supplemental Table 1.  A list of additional EMT associated Transcription Factors.  
Transcription factors with a minimum of 10 citations in the EMT literature.  “–“ indicates lack of 
a pertinent reference. 
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